{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:59:48Z","timestamp":1790272788921,"version":"4.1.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03393-5","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:53:44Z","timestamp":1790229224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review"],"prefix":"10.1007","volume":"43","author":[{"given":"Wahyu","family":"Widowati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Liliana","family":"Wargasetia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Sadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ita Margaretha","family":"Nainggolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizal","family":"Azis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safira Dinda","family":"Rifana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9997-3512","authenticated-orcid":false,"given":"Elham","family":"Rismani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5924-4366","authenticated-orcid":false,"given":"Massoud","family":"Vosough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"3393_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/jcm13196011","volume":"13","author":"C Mart\u00edn-Sierra","year":"2024","unstructured":"Mart\u00edn-Sierra C, Martins R, Coucelo M, Abrantes AM, Caetano Oliveira R, Tralh\u00e3o JG, et al. Tumor resection in hepatic carcinomas restores circulating T regulatory cells. J Clin Med. 2024;13:19.","journal-title":"J Clin Med"},{"key":"3393_CR2","doi-asserted-by":"publisher","first-page":"872353","DOI":"10.3389\/fimmu.2022.872353","volume":"13","author":"JS Xue","year":"2022","unstructured":"Xue JS, Ding ZN, Meng GX, Yan LJ, Liu H, Li HC, et al. The prognostic value of natural killer cells and their receptors\/ligands in hepatocellular carcinoma: a systematic review and meta-analysis. Front Immunol. 2022;13:872353.","journal-title":"Front Immunol"},{"issue":"2","key":"3393_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"AL Cheng","year":"2020","unstructured":"Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72(2):307\u201319.","journal-title":"J Hepatol"},{"issue":"3","key":"3393_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13666","volume":"206","author":"J Han","year":"2021","unstructured":"Han J, Ke C, Jiang B, Zhou H, Xu H, Xie X. Down-regulation of PR\/SET domain 10 underlies natural killer cell dysfunction in hepatocellular carcinoma. Clin Exp Immunol. 2021;206(3):366\u201377.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"3393_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025\u201336.","journal-title":"Nat Immunol"},{"issue":"7","key":"3393_CR6","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","volume":"169","author":"C Zheng","year":"2017","unstructured":"Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342\u2013e5616.","journal-title":"Cell"},{"key":"3393_CR7","doi-asserted-by":"crossref","unstructured":"Mantovani S, Oliviero B, Varchetta S, Mele D, Mondelli MU. Natural killer cell responses in hepatocellular carcinoma: implications for novel immunotherapeutic approaches. Cancers (Basel). 2020;12(4):926.","DOI":"10.3390\/cancers12040926"},{"key":"3393_CR8","doi-asserted-by":"crossref","unstructured":"Mantovani S, Varchetta S, Mele D, Donadon M, Torzilli G, Soldani C et al. An Anti-MICA\/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. Cancers (Basel). 2020;12(12):3583.","DOI":"10.3390\/cancers12123583"},{"issue":"2","key":"3393_CR9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","volume":"26","author":"M Yu","year":"2018","unstructured":"Yu M, Luo H, Fan M, Wu X, Shi B, Di S, et al. Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther. 2018;26(2):366\u201378.","journal-title":"Mol Ther"},{"key":"3393_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-018-0624-x","volume":"18","author":"F Hosseinzadeh","year":"2018","unstructured":"Hosseinzadeh F, Verdi J, Ai J, Hajighasemlou S, Seyhoun I, Parvizpour F, et al. Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell Int. 2018;18:133.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"3393_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/aps.2015.41","volume":"36","author":"C Sun","year":"2015","unstructured":"Sun C, Sun HY, Xiao WH, Zhang C, Tian ZG. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin. 2015;36(10):1191\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"29","key":"3393_CR12","doi-asserted-by":"publisher","first-page":"12022","DOI":"10.1002\/anie.202002145","volume":"59","author":"D Zhang","year":"2020","unstructured":"Zhang D, Zheng Y, Lin Z, Liu X, Li J, Yang H, et al. Equipping natural killer cells with specific targeting and checkpoint blocking aptamers for enhanced adoptive immunotherapy in solid tumors. Angew Chem Int Ed Engl. 2020;59(29):12022\u20138.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"3393_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1189\/jlb.0604360","volume":"78","author":"C Brando","year":"2005","unstructured":"Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, et al. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol. 2005;78(2):359\u201371.","journal-title":"J Leukoc Biol"},{"issue":"10","key":"3393_CR14","doi-asserted-by":"publisher","first-page":"e0164517","DOI":"10.1371\/journal.pone.0164517","volume":"11","author":"G Isitman","year":"2016","unstructured":"Isitman G, Tremblay-McLean A, Lisovsky I, Bruneau J, Lebouch\u00e9 B, Routy JP, et al. NK cells expressing the inhibitory killer immunoglobulin-like receptors (iKIR) KIR2DL1, KIR2DL3 and KIR3DL1 are less likely to be CD16\u2009+\u2009than Their iKIR negative counterparts. PLoS ONE. 2016;11(10):e0164517.","journal-title":"PLoS ONE"},{"issue":"1","key":"3393_CR15","doi-asserted-by":"publisher","first-page":"5618","DOI":"10.1038\/s41467-020-19322-7","volume":"11","author":"CK Schmidt","year":"2020","unstructured":"Schmidt CK, Medina-S\u00e1nchez M, Edmondson RJ, Schmidt OG. Engineering microrobots for targeted cancer therapies from a medical perspective. Nat Commun. 2020;11(1):5618.","journal-title":"Nat Commun"},{"key":"3393_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1126\/scisignal.aaz1965","volume":"13","author":"V Zurli","year":"2020","unstructured":"Zurli V, Montecchi T, Heilig R, Poschke I, Volkmar M, Wimmer G, et al. Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. Sci Signal. 2020;13:631.","journal-title":"Sci Signal"},{"issue":"6","key":"3393_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/cbf.3725","volume":"40","author":"K Dizaji Asl","year":"2022","unstructured":"Dizaji Asl K, Mazloumi Z, Majidi G, Kalarestaghi H, Sabetkam S, Rafat A. NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients. Cell Biochem Funct. 2022;40(6):559\u201368.","journal-title":"Cell Biochem Funct"},{"issue":"4","key":"3393_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1189\/jlb.1A0716-298RR","volume":"101","author":"F Zhang","year":"2017","unstructured":"Zhang F, Little A, Zhang H. Chronic alcohol consumption inhibits peripheral NK cell development and maturation by decreasing the availability of IL-15. J Leukoc Biol. 2017;101(4):1015\u201327.","journal-title":"J Leukoc Biol"},{"key":"3393_CR19","doi-asserted-by":"publisher","first-page":"1087155","DOI":"10.3389\/fimmu.2023.1087155","volume":"14","author":"P Rascle","year":"2023","unstructured":"Rascle P, Woolley G, Jost S, Manickam C, Reeves RK. NK cell education: Physiological and pathological influences. Front Immunol. 2023;14:1087155.","journal-title":"Front Immunol"},{"key":"3393_CR20","doi-asserted-by":"publisher","first-page":"688918","DOI":"10.3389\/fimmu.2021.688918","volume":"12","author":"G Santoni","year":"2021","unstructured":"Santoni G, Amantini C, Santoni M, Maggi F, Morelli MB, Santoni A. Mechanosensation and mechanotransduction in natural killer cells. Front Immunol. 2021;12:688918.","journal-title":"Front Immunol"},{"issue":"1","key":"3393_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.","journal-title":"Mol Cancer"},{"key":"3393_CR22","doi-asserted-by":"crossref","unstructured":"Alvarez M, Simonetta F, Baker J, Pierini A, Wenokur AS, Morrison AR et al. Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. JCI Insight. 2019;5(14):e127729.","DOI":"10.1172\/jci.insight.127729"},{"key":"3393_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3389\/fimmu.2018.01009","volume":"9","author":"NJW Easom","year":"2018","unstructured":"Easom NJW, Stegmann KA, Swadling L, Pallett LJ, Burton AR, Odera D, et al. IL-15 Overcomes hepatocellular carcinoma-induced NK cell dysfunction. Front Immunol. 2018;9:1009.","journal-title":"Front Immunol"},{"issue":"9","key":"3393_CR24","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/eji.201646559","volume":"46","author":"C Harmon","year":"2016","unstructured":"Harmon C, Robinson MW, Fahey R, Whelan S, Houlihan DD, Geoghegan J, et al. Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver. Eur J Immunol. 2016;46(9):2111\u201320.","journal-title":"Eur J Immunol"},{"issue":"6","key":"3393_CR25","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.4049\/jimmunol.1300164","volume":"191","author":"KA Holder","year":"2013","unstructured":"Holder KA, Stapleton SN, Gallant ME, Russell RS, Grant MD. Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions. J Immunol. 2013;191(6):3308\u201318.","journal-title":"J Immunol"},{"key":"3393_CR26","doi-asserted-by":"publisher","first-page":"5884531","DOI":"10.1155\/2022\/5884531","volume":"2022","author":"T Hao","year":"2022","unstructured":"Hao T, Yu H, Huang D, Liu Q. TMUB1 Correlated with immune infiltration is a prognostic marker for colorectal cancer. Dis Markers. 2022;2022:5884531.","journal-title":"Dis Markers"},{"issue":"2","key":"3393_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/03936155231169796","volume":"38","author":"DH Liu","year":"2023","unstructured":"Liu DH, Wen GM, Song CL, Xia P. Effect of secretory DKK3 on circulating CD56(bright) natural killer cells in patients with liver cancer. Int J Biol Markers. 2023;38(2):99\u2013104.","journal-title":"Int J Biol Markers"},{"issue":"3","key":"3393_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/hep.23054","volume":"50","author":"B Hoechst","year":"2009","unstructured":"Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50(3):799\u2013807.","journal-title":"Hepatology"},{"issue":"14","key":"3393_CR29","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1177\/15353702221092672","volume":"247","author":"Y Wei","year":"2022","unstructured":"Wei Y, Bingyu W, Lei Y, Xingxing Y. The antifibrotic role of natural killer cells in liver fibrosis. Exp Biol Med (Maywood). 2022;247(14):1235\u201343.","journal-title":"Exp Biol Med (Maywood)"},{"key":"3393_CR30","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wu Y, Shen W, Wang B, Yuan X. Crosstalk between NK cells and hepatic stellate cells in liver fibrosis (Review). Mol Med Rep. 2022;25(6):208.","DOI":"10.3892\/mmr.2022.12724"},{"key":"3393_CR31","doi-asserted-by":"crossref","unstructured":"Pi\u00f1eiro Fern\u00e1ndez J, Luddy KA, Harmon C, O\u2019Farrelly C. Hepatic tumor microenvironments and effects on NK cell phenotype and function. Int J Mol Sci. 2019;20(17):4131.","DOI":"10.3390\/ijms20174131"},{"issue":"7","key":"3393_CR32","doi-asserted-by":"publisher","first-page":"8970","DOI":"10.1002\/cam4.5579","volume":"12","author":"N Mukherjee","year":"2023","unstructured":"Mukherjee N, Ji N, Tan X, Chen CL, Noel ODV, Rodriguez-Padron M, et al. KLRF1, a novel marker of CD56(bright) NK cells, predicts improved survival for patients with locally advanced bladder cancer. Cancer Med. 2023;12(7):8970\u201380.","journal-title":"Cancer Med"},{"key":"3393_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1126\/scitranslmed.aba6322","volume":"13","author":"A Nishio","year":"2021","unstructured":"Nishio A, Bolte FJ, Takeda K, Park N, Yu ZX, Park H, et al. Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. Sci Transl Med. 2021;13:587.","journal-title":"Sci Transl Med"},{"issue":"2","key":"3393_CR34","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1182\/blood-2004-10-4035","volume":"106","author":"M Vitale","year":"2005","unstructured":"Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aric\u00f2 M, Moretta L, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood. 2005;106(2):566\u201371.","journal-title":"Blood"},{"issue":"11","key":"3393_CR35","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1182\/blood-2006-07-035519","volume":"109","author":"PK Epling-Burnette","year":"2007","unstructured":"Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109(11):4816\u201324.","journal-title":"Blood"},{"key":"3393_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fimmu.2018.00441","volume":"9","author":"FM Wensveen","year":"2018","unstructured":"Wensveen FM, Jelen\u010di\u0107 V, Poli\u0107 B. NKG2D: A master regulator of immune cell responsiveness. Front Immunol. 2018;9:441.","journal-title":"Front Immunol"},{"issue":"7","key":"3393_CR37","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1158\/2326-6066.CIR-15-0229","volume":"4","author":"T Kamiya","year":"2016","unstructured":"Kamiya T, Chang YH, Campana D. Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma. Cancer Immunol Res. 2016;4(7):574\u201381.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"3393_CR38","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/eji.201847688","volume":"48","author":"S Liu","year":"2018","unstructured":"Liu S, Xu M, Zhu C, Zhao Q, Zhou F. Taste receptor T1R1\/T1R3 promotes the tumoricidal activity of hepatic CD49a(+) CD49b(-) natural killer cells. Eur J Immunol. 2018;48(12):2031\u201341.","journal-title":"Eur J Immunol"},{"key":"3393_CR39","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","volume":"10","author":"AD Barrow","year":"2019","unstructured":"Barrow AD, Martin CJ, Colonna M. The natural cytotoxicity receptors in health and disease. Front Immunol. 2019;10:909.","journal-title":"Front Immunol"},{"issue":"4","key":"3393_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5114\/ceji.2019.92784","volume":"44","author":"X Zhu","year":"2019","unstructured":"Zhu X, Zhu R, Jian Z, Yu H. Laminarin enhances the activity of natural killer cells in immunosuppressed mice. Cent Eur J Immunol. 2019;44(4):357\u201363.","journal-title":"Cent Eur J Immunol"},{"key":"3393_CR41","doi-asserted-by":"publisher","first-page":"621225","DOI":"10.3389\/fimmu.2020.621225","volume":"11","author":"S Gaggero","year":"2020","unstructured":"Gaggero S, Witt K, Carlsten M, Mitra S. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy. Front Immunol. 2020;11:621225.","journal-title":"Front Immunol"},{"issue":"6013","key":"3393_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44\u20139.","journal-title":"Science"},{"key":"3393_CR43","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3389\/fimmu.2019.01999","volume":"10","author":"J Bi","year":"2019","unstructured":"Bi J, Tian Z. NK Cell Dysfunction and Checkpoint Immunotherapy. Front Immunol. 2019;10:1999.","journal-title":"Front Immunol"},{"key":"3393_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","volume":"31","author":"EO Long","year":"2013","unstructured":"Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227\u201358.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"3393_CR45","doi-asserted-by":"publisher","first-page":"1942673","DOI":"10.1080\/2162402X.2021.1942673","volume":"10","author":"L Yu","year":"2021","unstructured":"Yu L, Liu X, Wang X, Yan F, Wang P, Jiang Y, et al. TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus\u2013related hepatocellular carcinoma. Oncoimmunology. 2021;10(1):1942673.","journal-title":"Oncoimmunology"},{"issue":"4","key":"3393_CR46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nri3799","volume":"15","author":"L Martinet","year":"2015","unstructured":"Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. 2015;15(4):243\u201354.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3393_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173\u201385.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3393_CR48","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/hep.30347","volume":"70","author":"H Sun","year":"2019","unstructured":"Sun H, Huang Q, Huang M, Wen H, Lin R, Zheng M, et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology. 2019;70(1):168\u201383.","journal-title":"Hepatology"},{"issue":"1","key":"3393_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"issue":"2","key":"3393_CR50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200(2):108\u201319.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"3393_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335\u2013e463.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"3393_CR52","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.4049\/jimmunol.1401558","volume":"193","author":"RP Donnelly","year":"2014","unstructured":"Donnelly RP, Loftus RM, Keating SE, Liou KT, Biron CA, Gardiner CM, et al. mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. J Immunol. 2014;193(9):4477\u201384.","journal-title":"J Immunol"},{"key":"3393_CR53","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fimmu.2017.00367","volume":"8","author":"CM Gardiner","year":"2017","unstructured":"Gardiner CM, Finlay DK. What Fuels Natural Killers? Metabolism and NK Cell Responses. Front Immunol. 2017;8:367.","journal-title":"Front Immunol"},{"issue":"4","key":"3393_CR54","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.4049\/jimmunol.1402099","volume":"194","author":"MP Keppel","year":"2015","unstructured":"Keppel MP, Saucier N, Mah AY, Vogel TP, Cooper MA. Activation-specific metabolic requirements for NK Cell IFN-\u03b3 production. J Immunol. 2015;194(4):1954\u201362.","journal-title":"J Immunol"},{"key":"3393_CR55","doi-asserted-by":"publisher","first-page":"875072","DOI":"10.3389\/fimmu.2022.875072","volume":"13","author":"A Zecca","year":"2022","unstructured":"Zecca A, Barili V, Olivani A, Biasini E, Boni C, Fisicaro P, et al. Targeting stress sensor kinases in hepatocellular carcinoma-infiltrating human NK cells as a novel immunotherapeutic strategy for liver cancer. Front Immunol. 2022;13:875072.","journal-title":"Front Immunol"},{"issue":"5","key":"3393_CR56","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657\u201371.","journal-title":"Cell Metab"},{"issue":"2","key":"3393_CR57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cmet.2018.06.021","volume":"28","author":"J Cong","year":"2018","unstructured":"Cong J, Wang X, Zheng X, Wang D, Fu B, Sun R, et al. Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression. Cell Metab. 2018;28(2):243\u201355.e5.","journal-title":"Cell Metab"},{"issue":"9","key":"3393_CR58","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516\u201331.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3393_CR59","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.biochi.2004.09.018","volume":"86","author":"D Eberl\u00e9","year":"2004","unstructured":"Eberl\u00e9 D, Hegarty B, Bossard P, Ferr\u00e9 P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86(11):839\u201348.","journal-title":"Biochimie"},{"key":"3393_CR60","doi-asserted-by":"crossref","unstructured":"Sung PS, Jang JW. Natural killer cell dysfunction in hepatocellular carcinoma: pathogenesis and clinical implications. Int J Mol Sci. 2018;19(11):3648.","DOI":"10.3390\/ijms19113648"},{"issue":"7","key":"3393_CR61","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/ijc.32278","volume":"145","author":"Z Li","year":"2019","unstructured":"Li Z, Zhou J, Zhang J, Li S, Wang H, Du J. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5. Int J Cancer. 2019;145(7):1946\u201357.","journal-title":"Int J Cancer"},{"key":"3393_CR62","doi-asserted-by":"crossref","unstructured":"Yeo ECF, Brown MP, Gargett T, Ebert LM. The Role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy. Cells. 2021;10(3):607.","DOI":"10.3390\/cells10030607"},{"issue":"8","key":"3393_CR63","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051\u20137.","journal-title":"Blood"},{"key":"3393_CR64","doi-asserted-by":"publisher","first-page":"1206737-44","DOI":"10.1155\/2018\/1206737","volume":"2018","author":"P Liu","year":"2018","unstructured":"Liu P, Chen L, Zhang H. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy. J Immunol Res. 2018;2018:1206737-44.","journal-title":"J Immunol Res"},{"issue":"11","key":"3393_CR65","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-07-4744","volume":"14","author":"S Armeanu","year":"2008","unstructured":"Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res. 2008;14(11):3520\u20138.","journal-title":"Clin Cancer Res"},{"key":"3393_CR66","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.3389\/fimmu.2019.02836","volume":"10","author":"P Minetto","year":"2019","unstructured":"Minetto P, Guolo F, Pesce S, Greppi M, Obino V, Ferretti E, et al. Harnessing NK cells for cancer treatment. Front Immunol. 2019;10:2836.","journal-title":"Front Immunol"},{"key":"3393_CR67","doi-asserted-by":"publisher","first-page":"175883591986269","DOI":"10.1177\/1758835919862692","volume":"11","author":"W Xu","year":"2019","unstructured":"Xu W, Liu K, Chen M, Sun JY, McCaughan GW, Lu XJ, et al. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Ther Adv Med Oncol. 2019;11:1758835919862692.","journal-title":"Ther Adv Med Oncol"},{"key":"3393_CR68","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","volume":"10","author":"W Hu","year":"2019","unstructured":"Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Front Immunol. 2019;10:1205.","journal-title":"Front Immunol"},{"issue":"2","key":"3393_CR69","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181\u2013. \u2013\u200992.e5.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"3393_CR70","doi-asserted-by":"publisher","first-page":"e27745","DOI":"10.1002\/pbc.27745","volume":"66","author":"K Haines","year":"2019","unstructured":"Haines K, Sarabia SF, Alvarez KR, Tomlinson G, Vasudevan SA, Heczey AA, et al. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. Pediatr Blood Cancer. 2019;66(7):e27745.","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"3393_CR71","doi-asserted-by":"publisher","first-page":"e064526","DOI":"10.1136\/bmjopen-2022-064526","volume":"12","author":"M Ohira","year":"2022","unstructured":"Ohira M, Kobayashi T, Tanaka Y, Imaoka Y, Sato K, Imaoka K, et al. Adoptive immunotherapy with natural killer cells from peripheral blood CD34(+) stem cells to prevent hepatocellular carcinoma recurrence after curative hepatectomy: a study protocol for an open-label, single-arm phase I study. BMJ Open. 2022;12(11):e064526.","journal-title":"BMJ Open"},{"issue":"1","key":"3393_CR72","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12967-026-07725-x","volume":"24","author":"F Yang","year":"2026","unstructured":"Yang F, Gong Y, Zheng X, Ni B, Lu J, Chen X, et al. NK cell infusion is well-tolerated and shows preliminary efficacy in patients with recurrent hepatocellular carcinoma post-liver transplantation: a phase I trial. J Transl Med. 2026;24(1):261.","journal-title":"J Transl Med"},{"key":"3393_CR73","doi-asserted-by":"publisher","first-page":"1167266","DOI":"10.3389\/fonc.2023.1167266","volume":"13","author":"J Wang","year":"2023","unstructured":"Wang J, Metheny L. Umbilical cord blood derived cellular therapy: advances in clinical development. Front Oncol. 2023;13:1167266.","journal-title":"Front Oncol"},{"issue":"10473","key":"3393_CR74","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025;405(10473):127\u201336.","journal-title":"Lancet"},{"issue":"5","key":"3393_CR75","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","volume":"25","author":"H Klingemann","year":"2023","unstructured":"Klingemann H. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy. 2023;25(5):451\u20137.","journal-title":"Cytotherapy"},{"issue":"2","key":"3393_CR76","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/imm.13624","volume":"169","author":"L Chen","year":"2023","unstructured":"Chen L, Liu S, Adah D, Sun Q, Liang Z, Ho M, et al. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma. Immunology. 2023;169(2):204\u201318.","journal-title":"Immunology"},{"issue":"1","key":"3393_CR77","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","volume":"13","author":"A Yilmaz","year":"2020","unstructured":"Yilmaz A, Cui H, Caligiuri MA, Yu J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol. 2020;13(1):168.","journal-title":"J Hematol Oncol"},{"key":"3393_CR78","doi-asserted-by":"publisher","first-page":"720501","DOI":"10.3389\/fonc.2021.720501","volume":"11","author":"H Lu","year":"2021","unstructured":"Lu H, Zhao X, Li Z, Hu Y, Wang H. From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies. Front Oncol. 2021;11:720501.","journal-title":"Front Oncol"},{"issue":"1","key":"3393_CR79","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","volume":"11","author":"HC Tseng","year":"2020","unstructured":"Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11(1):4810.","journal-title":"Nat Commun"},{"key":"3393_CR80","doi-asserted-by":"publisher","first-page":"103046","DOI":"10.1016\/j.ctrv.2025.103046","volume":"141","author":"R Elahi","year":"2025","unstructured":"Elahi R, Alami Idrissi Y, Saeed A. CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation. Cancer Treat Rev. 2025;141:103046.","journal-title":"Cancer Treat Rev"},{"key":"3393_CR81","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3389\/fphar.2020.01089","volume":"11","author":"S Yang","year":"2020","unstructured":"Yang S, Cao B, Zhou G, Zhu L, Wang L, Zhang L, et al. Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer. Front Pharmacol. 2020;11:1089.","journal-title":"Front Pharmacol"},{"issue":"7","key":"3393_CR82","doi-asserted-by":"publisher","first-page":"e1440169","DOI":"10.1080\/2162402X.2018.1440169","volume":"7","author":"Y Wang","year":"2018","unstructured":"Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology. 2018;7(7):e1440169.","journal-title":"Oncoimmunology"},{"key":"3393_CR83","doi-asserted-by":"crossref","unstructured":"Pawlowski KD, Duffy JT, Tiwari A, Zannikou M, Balyasnikova IV. Bi-specific killer cell engager enhances NK cell activity against interleukin-13 receptor alpha-2 positive gliomas. Cells. 2023;12(13):1716.","DOI":"10.3390\/cells12131716"},{"key":"3393_CR84","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1\/PD-L1 based combination immunotherapy to boost antigen-specific CD8(+) T Cell response in hepatocellular carcinoma. cancers (basel). 2021;13(8):1922.","DOI":"10.3390\/cancers13081922"},{"key":"3393_CR85","doi-asserted-by":"publisher","first-page":"822298","DOI":"10.3389\/fimmu.2022.822298","volume":"13","author":"KE Ruppel","year":"2022","unstructured":"Ruppel KE, Fricke S, K\u00f6hl U, Schmiedel D. Taking lessons from CAR-T cells and going beyond: tailoring design and signaling for CAR-NK cells in cancer therapy. Front Immunol. 2022;13:822298.","journal-title":"Front Immunol"},{"issue":"5","key":"3393_CR86","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri2744","volume":"10","author":"LM Weiner","year":"2010","unstructured":"Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317\u201327.","journal-title":"Nat Rev Immunol"},{"key":"3393_CR87","doi-asserted-by":"publisher","first-page":"1060905","DOI":"10.3389\/fimmu.2023.1060905","volume":"14","author":"PR Kennedy","year":"2023","unstructured":"Kennedy PR, Vallera DA, Ettestad B, Hallstrom C, Kodal B, Todhunter DA, et al. A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. Front Immunol. 2023;14:1060905.","journal-title":"Front Immunol"},{"key":"3393_CR88","unstructured":"NAYA Biosciences I. NAYA Biosciences Announces Initiation of Phase 1\/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma2024. Available from: https:\/\/6ix.com\/news\/naya-biosciences-announces-initiation-of-phase-12a-clinical-trial-for-its-gpc3-targeted-nk-engager-bispecific-antibody-in-patients-with-hepatocellular-carcinoma"},{"key":"3393_CR89","doi-asserted-by":"crossref","unstructured":"Arulanandam A, Lin L, Chang HM, Cerutti M, Choblet S, Gao P et al. Derivation and preclinical characterization of CYT-303, a novel NKp46-NK cell engager targeting GPC3. Cells. 2023;12(7):996.","DOI":"10.3390\/cells12070996"},{"key":"3393_CR90","doi-asserted-by":"publisher","first-page":"1599764","DOI":"10.3389\/fimmu.2025.1599764","volume":"16","author":"L Chen","year":"2025","unstructured":"Chen L, Zhu Y, Feng M, Zuo D, Chen G, Ji K. Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody. Front Immunol. 2025;16:1599764.","journal-title":"Front Immunol"},{"key":"3393_CR91","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fcell.2019.00233","volume":"7","author":"RY Zhang","year":"2019","unstructured":"Zhang RY, Wei D, Liu ZK, Yong YL, Wei W, Zhang ZY, et al. Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy. Front Cell Dev Biol. 2019;7:233.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3393_CR92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40164-024-00522-6","volume":"13","author":"L Egli","year":"2024","unstructured":"Egli L, Kaulfuss M, Mietz J, Picozzi A, Verhoeyen E, M\u00fcnz C, et al. CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. Exp Hematol Oncol. 2024;13(1):51.","journal-title":"Exp Hematol Oncol"},{"key":"3393_CR93","doi-asserted-by":"publisher","first-page":"104912","DOI":"10.1016\/j.critrevonc.2025.104912","volume":"214","author":"F Zhang","year":"2025","unstructured":"Zhang F, Soleimani Samarkhazan H, Pooraskari Z, Bayani A, Beyond. CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy. Crit Rev Oncol Hematol. 2025;214:104912.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3393_CR94","doi-asserted-by":"crossref","unstructured":"Yang G, Nikkhoi SK, Owji H, Li G, Massumi M, Cervelli J et al. A novel tetravalent bispecific immune cell engager activates natural killer cells to kill cancer cells without mediating fratricide. Antibodies (Basel). 2024;13(3):75.","DOI":"10.3390\/antib13030075"},{"issue":"14","key":"3393_CR95","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","volume":"22","author":"DA Vallera","year":"2016","unstructured":"Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, et al. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33\u2009+\u2009Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016;22(14):3440\u201350.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3393_CR96","doi-asserted-by":"publisher","first-page":"344","DOI":"10.62347\/PMVN1173","volume":"14","author":"A Eresen","year":"2024","unstructured":"Eresen A, Pang Y, Zhang Z, Hou Q, Chen Z, Yu G, et al. Sorafenib plus memory like natural killer cell combination therapy in hepatocellular carcinoma. Am J Cancer Res. 2024;14(1):344\u201354.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"3393_CR97","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/hep.26328","volume":"57","author":"MF Sprinzl","year":"2013","unstructured":"Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology. 2013;57(6):2358\u201368.","journal-title":"Hepatology"},{"issue":"2","key":"3393_CR98","first-page":"337","volume":"11","author":"J Yang","year":"2021","unstructured":"Yang J, Eresen A, Scotti A, Cai K, Zhang Z. Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma. Am J Cancer Res. 2021;11(2):337\u201349.","journal-title":"Am J Cancer Res"},{"key":"3393_CR99","doi-asserted-by":"publisher","first-page":"102131","DOI":"10.1016\/j.toxrep.2025.102131","volume":"15","author":"F Hosseinzadeh","year":"2025","unstructured":"Hosseinzadeh F, Komeili Movahhed T, Dolati M, Kheirkhah AH, Beheshtizadeh N, Verdi J. Assessment of the main signaling pathways involved in the combined therapy of hepatocellular carcinoma using Sorafenib and NK cells in xenograft mice model. Toxicol Rep. 2025;15:102131.","journal-title":"Toxicol Rep"},{"issue":"1","key":"3393_CR100","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s43856-023-00390-x","volume":"3","author":"M Yamauchi","year":"2023","unstructured":"Yamauchi M, Ono A, Amioka K, Fujii Y, Nakahara H, Teraoka Y, et al. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma. Commun Med (Lond). 2023;3(1):152.","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"3393_CR101","doi-asserted-by":"publisher","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188391.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"11","key":"3393_CR102","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1016\/j.ymthe.2024.09.025","volume":"32","author":"WN Liu","year":"2024","unstructured":"Liu WN, Harden SL, Tan SLW, Tan RJR, Fong SY, Tan SY, et al. Single-cell RNA sequencing reveals anti-tumor potency of CD56(+) NK cells and CD8(+) T cells in humanized mice via PD-1 and TIGIT co-targeting. Mol Ther. 2024;32(11):3895\u2013914.","journal-title":"Mol Ther"},{"issue":"4","key":"3393_CR103","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41388-020-01561-z","volume":"40","author":"F Wang","year":"2021","unstructured":"Wang F, Lau JKC, Yu J. The role of natural killer cell in gastrointestinal cancer: killer or helper. Oncogene. 2021;40(4):717\u201330.","journal-title":"Oncogene"},{"issue":"1","key":"3393_CR104","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.1038\/s41598-017-05500-z","volume":"7","author":"A Chen","year":"2017","unstructured":"Chen A, Zhang Y, Meng G, Jiang D, Zhang H, Zheng M, et al. Oncolytic measles virus enhances antitumour responses of adoptive CD8(+)NKG2D(+) cells in hepatocellular carcinoma treatment. Sci Rep. 2017;7(1):5170.","journal-title":"Sci Rep"},{"key":"3393_CR105","doi-asserted-by":"publisher","first-page":"38407","DOI":"10.1038\/srep38407","volume":"6","author":"K Goto","year":"2016","unstructured":"Goto K, Annan DA, Morita T, Li W, Muroyama R, Matsubara Y, et al. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study. Sci Rep. 2016;6:38407.","journal-title":"Sci Rep"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03393-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03393-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03393-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:02:48Z","timestamp":1790269368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03393-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":105,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3393"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03393-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Permission to reproduce material from other sources","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"293"}}